Studies have found that heparin can prevent the death of sepsis dependent on caspase-11

It is understood that heparin is a mammalian polysaccharose, but also a widely used treatment of thrombosis disease anticoagulant drugs.
Ben Lu of Central South University found that heparin prevents sepsis deaths from caspase-11 dependence, independent of its anticoagulant properties.
the study was published online today in Immunity, a leading international academic journal.
have shown that heparin prevents caspase-11-dependent immune response and lethality in sepsis, independent of its anticoagulant properties.
, a chemically modified form of heparin or anticoagulant-free, inhibits the interaction of the alarm protein HMGB1-lipid polysaccharides (LPS) and prevents the degradation of the macrophage glycosin of acetylheparinase.
these events prevent cytostic transmission of LPS in macrophages and activation of caspase-11, a deadly cytosphageal LPS subject that mediates sepsis.
patients with sepsis who received heparin treatment had a higher survival rate than those who did not receive heparin treatment.
the identification of this previously unknown heparin function established a link between congenital immune response and clotting.
it can also improve the outcome of sepsis, which is the leading cause of death from infection-induced immunodeficiability disorders.
although it is relatively clear how heparin plays its anticoagulant role, the immunomodulation mechanism that heparin can achieve remains a mystery.
(）